Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Company on 31 January 2025.Powered by Capital Market - Live News

TARO Pharmaceuticals Inc., a subsidiary of Sun Pharmaceutical Industries, has entered into an agreement with Antibe Therapeutics Inc., Canada, pursuant to which Sun Pharma has agreed to acquire 100% stake in Antibe Therapeutics Inc.Antibe Therapeutics Inc. (Antibe) is an Ontario, Canada incorporated corporation based in Ontario, Canada. It is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation. Antibe is currently being managed by a court appointed receiver, and the receiver is authorized to carry out the sale of Antibe. Powered by Capital Market - Live News

Sun Pharmaceuticals Industries announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 21 January 2025.Powered by Capital Market - Live News

Net profit of Sun Pharmaceuticals Industries rose 27.98% to Rs 3040.16 crore in the quarter ended September 2024 as against Rs 2375.51 crore during the previous quarter ended September 2023. Sales rose 10.51% to Rs 13264.22 crore in the quarter ended September 2024 as against Rs 12003.11 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales13264.2212003.11 11 OPM %29.7026.49 - PBDT4223.793423.70 23 PBT3597.882790.88 29 NP3040.162375.51 28 Powered by Capital Market - Live News

Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Company on 28 October 2024Powered by Capital Market - Live News